Szpital Uniwersytecki Nr 1 Im. Dr. A. Jurasza W Bydgoszczy
- Address
- lock Available on a paid plan
Dr. A. Jurasz University Hospital No. 1 in Bydgoszcz - Advanced Clinical Research Center
Dr. A. Jurasz University Hospital No. 1 in Bydgoszcz stands as a prominent clinical research institution with extensive expertise in cardiovascular medicine, oncology, and specialized therapeutic interventions. The center demonstrates particular strength in acute coronary syndrome research, investigating novel antiplatelet strategies and advanced cardiac therapeutics, while also conducting groundbreaking trials in regenerative medicine and rare disease treatments.
- Cardiovascular research including acute coronary syndrome, heart failure, atrial fibrillation, and perioperative myocardial injury prevention
- Pediatric and adult hematologic malignancies, particularly acute lymphoblastic leukemia and lymphomas with innovative CAR-T cell therapies
- Rare diseases including neurofibromatosis type 1, Takotsubo syndrome, and Down syndrome-associated myeloid leukemia
- Nephrology and immunology focusing on nephrotic syndrome, membranous nephropathy, and chronic urticaria
The hospital's research portfolio encompasses multiple Phase II and III trials evaluating cutting-edge therapies, from somatic cell-based treatments for urinary incontinence to targeted molecular therapies for rare genetic conditions. The center actively participates in international collaborative protocols, including the AIEOP-BFM consortium for pediatric leukemia and multi-national cardiovascular outcome studies. With expertise spanning from novel anticoagulation strategies to advanced biologics and small molecule inhibitors, the facility demonstrates comprehensive capabilities in translating innovative medical research into clinical practice across diverse therapeutic areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 10 therapeutic areas and 15 of 78 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 76 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 16 by active trials.
- 1Nicolaus Copernicus University2active
lock +15 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Medical University Of Gdansk4trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Szpital Uniwersytecki Nr 1 Im. Dr. A. Jurasza W Bydgoszczy
lock Showing 1 of 35 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 78 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 7 | Unknown | 2017-10-02 | 2024-11-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.